In agreement with our results, some mammal studies have demonstrated that CA and HT regulate WAT mass by suppressing lipogenic enzyme activity and claimed that PPARγ antagonists can be used to treat hyperlipidemia [74,75]. This evidence concerns the gene PPARG and hyperlipidemia.